PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: A homologous recombination deficiency (HRD) is a target for PARP inhibitors, and HRD status now serves as a biomarker for indicating the appropriate time to apply these agents [25,35,36,37].